Orris

1.Find out what is BLIND LOOP SYNDROME and VIT B12 DEFICIENCY 2.Who is RAM NATH CHOPRA and what is the importance of AUG 17 IN PHARMCY 3.Prasugrel is preferred over clopidogrel in diabetics why?

Reading File
Searching the Web

Ram Nath Chopra father of pharmacology India August 17 pharmacy day

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

prasugrel clopidogrel diabetes

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File

1. Blind Loop Syndrome and Vitamin B12 Deficiency

Blind loop syndrome is a rare condition caused by bacterial overgrowth in a stagnant (blind) segment of the small bowel. It arises when bowel stasis develops in areas produced by strictures, stenosis, fistulas, diverticula (e.g., jejunoileal or Meckel diverticulum), or a surgically created blind segment (as in a Billroth II afferent loop). Normally the upper GI tract holds fewer than 10^3 bacteria/mL, mostly gram-positive aerobes. With stasis, aerobic and anaerobic bacteria (Bacteroides, anaerobic lactobacilli, coliforms, enterococci) proliferate excessively.
Why it causes B12 deficiency: the overgrowing bacteria directly compete with the host for dietary vitamin B12, consuming it before it can be absorbed in the terminal ileum. This produces a systemic B12 deficiency and megaloblastic anemia. The bacteria also deconjugate bile salts, which additionally causes steatorrhea and fat-soluble vitamin deficiency.
Clinical picture: diarrhea, steatorrhea, megaloblastic anemia, weight loss, abdominal pain, and neurologic disturbances (from B12 deficiency - peripheral neuropathy, subacute combined degeneration).
Diagnosis: carbohydrate/hydrogen breath tests or intestinal fluid culture. Historically, the Schilling test showed low urinary B12 excretion that was not corrected by adding intrinsic factor (distinguishing it from pernicious anemia), but was corrected after a course of antibiotics - confirming bacteria, not intrinsic factor deficiency, as the cause.
Treatment: parenteral vitamin B12, plus broad-spectrum antibiotics (tetracycline classically; rifaximin or metronidazole now preferred due to less resistance), typically a 7-10 day course. Definitive cure requires surgical correction of the underlying stagnant loop if antibiotics are needed repeatedly.
  • Sabiston Textbook of Surgery, "Blind Loop Syndrome" and "Afferent Loop Syndrome" sections
  • Maingot's Abdominal Operations, "Jejunoileal Diverticula"
  • Henry's Clinical Diagnosis and Management by Laboratory Methods, "Defective Absorption of Cobalamin"

2. Sir Ram Nath Chopra and August 17 in Pharmacy

Sir Ram Nath Chopra (17 August 1882 - 13 June 1973) was an Indian Medical Service officer widely regarded as the "Father of Indian Pharmacology." Born in Gujranwala, Punjab (now Pakistan), he studied Natural Sciences at Downing College, Cambridge, working under pharmacologist Walter E. Dixon, and later trained in pharmacology in England before returning to India.
He established India's first pharmacology research laboratory (Calcutta School of Tropical Medicine, later School of Tropical Medicine and the Drug Research Laboratory in Jammu) and dedicated his career to making India self-sufficient in drug production through scientific evaluation of indigenous and traditional medicinal plants (e.g., work on chaulmoogra oil for leprosy, and Indian medicinal herbs). He was also a leading authority on drug addiction and narcotics control in India, and served on international drug-control bodies. He was knighted in 1941 and made a Companion of the Order of the Indian Empire (CIE) in 1934.
Importance of August 17: Because Chopra was born on 17 August 1882, this date is observed in India as National Pharmacology Day, commemorated especially by pharmacy and pharmacology institutions to honor his foundational contributions to establishing pharmacology as a scientific discipline in India and promoting indigenous drug research.

3. Why Prasugrel Is Preferred Over Clopidogrel in Diabetics

Both are thienopyridine prodrugs that irreversibly block the platelet P2Y12 ADP receptor, but they differ in how they get activated and how reliably they work - and this matters especially in diabetic patients:
a) Metabolic activation difference
  • Clopidogrel needs a two-step hepatic CYP450 oxidation (via CYP3A4, CYP3A5, CYP2C9, CYP1A2, CYP2B6, and critically CYP2C19) to form its active metabolite. Only a small fraction of the absorbed drug (~15%) is converted to active form.
  • Prasugrel needs only a one-step hepatic metabolism, giving a more favorable, predictable pharmacokinetic profile: faster onset, more potent and consistent platelet inhibition, and much lower inter-individual variability.
b) The diabetes-specific problem with clopidogrel Diabetic patients characteristically have increased baseline platelet reactivity (due to accelerated atherogenesis, hyperglycemia-driven prothrombotic state, and often obesity). On top of this, diabetics have a higher prevalence of "clopidogrel resistance" - inadequate platelet inhibition on standard doses - driven by:
  • Patient-related factors such as diabetes itself, smoking, and proximity to an acute coronary event, which independently blunt clopidogrel's antiplatelet effect
  • Higher frequency of CYP2C19 loss-of-function variants/reduced hepatic activation in this population, leading to unpredictable, often insufficient active-metabolite generation
Because clopidogrel's effect depends entirely on this variable two-step bioactivation, diabetics are disproportionately likely to be "poor responders," leaving them under-protected against stent thrombosis and recurrent ischemic events.
c) Why prasugrel overcomes this Prasugrel's simpler, more efficient one-step activation produces more complete and consistent P2Y12 blockade regardless of the CYP2C19 variability that undermines clopidogrel. In the pivotal TRITON-TIMI 38 trial, the diabetic subgroup showed a particularly pronounced reduction in ischemic events with prasugrel compared with clopidogrel, without the excess bleeding penalty seen in other high-risk subgroups (elderly, low body weight, prior stroke/TIA) - which is why current practice favors prasugrel over clopidogrel in diabetic patients undergoing PCI, provided they don't have contraindications (prior stroke/TIA, age >75, or weight <60 kg, where net harm was seen).
  • Fuster and Hurst's The Heart, 15th Edition, "P2Y Receptor Inhibitors"
  • Lippincott Illustrated Reviews: Pharmacology, "Choice of Antiplatelet Therapy Based on Genetic Results"
Evidence check: A recent PubMed search (2023-2025) for systematic reviews/meta-analyses on prasugrel vs. clopidogrel found studies mainly focused on CYP2C19 genotype-guided therapy in stroke patients (PMID 41450128) and network meta-analyses of low-dose prasugrel in ischemic heart disease (PMID 40489021) - these do not contradict the diabetic-specific rationale above but reinforce that CYP2C19-related variability remains the central mechanistic argument for choosing prasugrel/ticagrelor over clopidogrel in higher-risk populations.
This is a shared conversation. Sign in to Orris to start your own chat.